STOCK TITAN

ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ADMA Biologics (Nasdaq: ADMA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company's presentation is scheduled for Monday, January 13, 2025, at 10:30 a.m. PT.

As an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics, ADMA will make its presentation available through a live audio webcast accessible via the investor section of the company's website under 'Events & Webcasts'. An archived version of the webcast will be available approximately two hours after the event.

ADMA Biologics (Nasdaq: ADMA) ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference a San Francisco, California. La presentazione dell'azienda è programmata per lunedì 13 gennaio 2025, alle 10:30 ora del Pacifico.

In quanto azienda biopharma commerciale a ciclo completo, focalizzata sulla produzione, marketing e sviluppo di biologici specializzati, ADMA renderà la sua presentazione disponibile tramite un webcast audio live accessibile nella sezione investitori del sito web dell'azienda sotto 'Eventi & Webcast'. Una versione archiviata del webcast sarà disponibile circa due ore dopo l'evento.

ADMA Biologics (Nasdaq: ADMA) ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan en San Francisco, California. La presentación de la empresa está programada para lunes 13 de enero de 2025, a las 10:30 a.m. PT.

Como una compañía biofarmacéutica comercial integral enfocada en la fabricación, comercialización y desarrollo de biológicos especializados, ADMA hará su presentación disponible a través de un webcast de audio en vivo accesible a través de la sección para inversores del sitio web de la empresa bajo 'Eventos y Webcasts'. Una versión archivada del webcast estará disponible aproximadamente dos horas después del evento.

ADMA Biologics (Nasdaq: ADMA)는 캘리포니아 샌프란시스코에서 열리는 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 발표는 2025년 1월 13일 월요일, 오전 10시 30분 PT에 예정되어 있습니다.

전문 생물학 제품의 제조, 마케팅 및 개발에 집중하는 완전 상업 생물 제약 회사로서, ADMA는 회사 웹사이트의 투자자 섹션에서 '이벤트 및 웹캐스트' 아래에서 접근 가능한 실시간 오디오 웹캐스트를 통해 발표를 제공합니다. 이벤트 종료 약 두 시간 후에 웹캐스트의 보관 버전도 제공됩니다.

ADMA Biologics (Nasdaq: ADMA) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare à San Francisco, Californie. La présentation de l'entreprise est prévue pour lundi 13 janvier 2025, à 10h30 PT.

En tant qu'entreprise biopharmaceutique commerciale intégrale axée sur la fabrication, le marketing et le développement de biologiques spécialisés, ADMA mettra sa présentation à disposition via un webcast audio en direct accessible via la section investisseurs du site web de l'entreprise sous 'Événements & Webcasts'. Une version archivée du webcast sera disponible environ deux heures après l'événement.

ADMA Biologics (Nasdaq: ADMA) hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference in San Francisco, Kalifornien, bekannt gegeben. Die Präsentation des Unternehmens ist für Montag, den 13. Januar 2025, um 10:30 Uhr PT angesetzt.

Als ein praktikant ausgerichtetes biopharmazeutisches Unternehmen, das sich auf die Herstellung, Vermarktung und Entwicklung von Spezialbiologika konzentriert, wird ADMA seine Präsentation über ein Live-Audio-Webcast verfügbar machen, der über den Investorenbereich der Unternehmenswebsite unter 'Veranstaltungen & Webcasts' zugänglich ist. Eine archivierte Version des Webcasts wird ungefähr zwei Stunden nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.

A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty biologics and human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com


FAQ

When is ADMA Biologics presenting at the J.P. Morgan Healthcare Conference 2025?

ADMA Biologics is scheduled to present on Monday, January 13, 2025, at 10:30 a.m. PT at the J.P. Morgan Healthcare Conference in San Francisco.

How can investors watch ADMA Biologics' J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live audio webcast available in the 'Events & Webcasts' section of ADMA's investor relations website at https://ir.admabiologics.com/events-webcasts.

Will ADMA's J.P. Morgan Healthcare Conference presentation be available after the event?

Yes, an archived version of the webcast will be available on ADMA's company website approximately two hours after the presentation.

What is the duration of the 2025 J.P. Morgan Healthcare Conference where ADMA is presenting?

The 43rd Annual J.P. Morgan Healthcare Conference runs from January 13-16, 2025, in San Francisco, California.

ADMA Biologics, Inc.

NASDAQ:ADMA

ADMA Rankings

ADMA Latest News

ADMA Stock Data

4.35B
227.30M
2.51%
91.78%
5.15%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
RAMSEY